A Phase 1 Research Study to Evaluate Safety, Tolerability, and Pharmacokinetics of WVE-006 in Healthy Participants With Wild-type AAT Expression (RestorAATion-1)

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 14, 2023

Primary Completion Date

February 13, 2025

Study Completion Date

February 13, 2025

Conditions

Alpha-1 Antitrypsin Deficiency

Interventions

DRUG

WVE-006

RNA editing oligonucleotide

Trial Locations (1)

Simbec-Orion Clinical Pharmacology,, Merthyr Tydfil

All Listed Sponsors

lead

Wave Life Sciences Ltd.

INDUSTRY